Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microneedling plus topical imiquimod for psoriatic nails
ChiCTR2600116372Phase 4Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Jan 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imiquimod in psoriasis (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoints: Nail Psoriasis Severity Index (NAPSI) and Modified Nail Psoriasis Severity Index (mNAPSI). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
imiquimod
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR2600116372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116372.